Gene Therapy Shows Lasting Hearing Improvement in OTOF-Related Deafness Trial

In Brief

This trial marks a significant step in treating inherited deafness, offering hope for long-term hearing restoration in affected individuals.

Key Facts

• Gene therapy targeting OTOF-related deafness was tested in a multicentre clinical trial.
• Researchers report that the therapy improved hearing in 90% of patients with inherited deafness.
• Some patients experienced hearing restoration lasting up to 2.5 years after treatment.
• The trial included both children and adults, with participants as old as 32 years regaining hearing.
• This is the largest trial of its kind for gene therapy in inherited deafness.

What Happened

A multicentre clinical trial tested gene therapy for OTOF-related inherited deafness, with patients experiencing restored hearing that persisted for up to 2.5 years.

Why It Matters

The results suggest gene therapy could provide a durable treatment option for individuals with certain forms of genetic deafness, potentially changing the standard of care for this rare condition.

What's Next

Researchers may conduct further studies to assess long-term safety and effectiveness, and regulatory review could follow if results continue to be positive.